This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Nov 4;351(19):1934-6.

doi: 10.1056/NEJMp048254. Epub 2004 Oct 31.

Treating diabetic nephropathy--are there only economic issues?

William E Mitch¹

Affiliations

PMID: 15516698
DOI: 10.1056/NEJMp048254

Comment

Treating diabetic nephropathy--are there only economic issues?

William E Mitch. N Engl J Med. 2004.

. 2004 Nov 4;351(19):1934-6.

doi: 10.1056/NEJMp048254. Epub 2004 Oct 31.

Author

William E Mitch¹

Affiliation

¹ Renal Division, University of Texas Medical Branch, Galveston, USA

PMID: 15516698
DOI: 10.1056/NEJMp048254

No abstract available

PubMed Disclaimer

Comment on

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Barnett AH, et al. N Engl J Med. 2004 Nov 4;351(19):1952-61. doi: 10.1056/NEJMoa042274. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516696 Clinical Trial.
Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Ruggenenti P, et al. N Engl J Med. 2004 Nov 4;351(19):1941-51. doi: 10.1056/NEJMoa042167. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516697 Clinical Trial.

Similar articles

Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED, Preddie DC. Crook ED, et al. Ethn Dis. 2002 Fall;12(4):S3-49-52. Ethn Dis. 2002. PMID: 12477155
Diabetic nephropathy.
Goto A. Goto A. N Engl J Med. 2002 Sep 19;347(12):947-8; author reply 947-8. doi: 10.1056/NEJM200209193471218. N Engl J Med. 2002. PMID: 12239270 No abstract available.
[Threatened diabetic nephropathy. Early administration of ACE inhibitors and AT1 blockers].
Einecke U. Einecke U. MMW Fortschr Med. 2002 Apr 11;144(15):14. MMW Fortschr Med. 2002. PMID: 12004443 German. No abstract available.
Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?
Hollenberg NK. Hollenberg NK. Arch Intern Med. 2004 Jan 26;164(2):125-30. doi: 10.1001/archinte.164.2.125. Arch Intern Med. 2004. PMID: 14744834 Review. No abstract available.
[Considerations on the treatment of incipient diabetic nephropathy (lst of 2 parts)].
Pérez Blanco FJ, Manzanares L, Moreno G, Cabello MJ. Pérez Blanco FJ, et al. An Med Interna. 1996 Apr;13(4):193-7. An Med Interna. 1996. PMID: 8688481 Review. Spanish.

See all similar articles

Cited by

Pursuing Diabetic Nephropathy through Aqueous Humor Proteomics Analysis.
Chen H, Wang T, Wang E, Li N, Min H. Chen H, et al. Oxid Med Cell Longev. 2022 Sep 29;2022:5945828. doi: 10.1155/2022/5945828. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36211816 Free PMC article.
Diabetic nephropathy: lessons from the mouse.
Vashistha H, Meggs L. Vashistha H, et al. Ochsner J. 2013 Spring;13(1):140-6. Ochsner J. 2013. PMID: 23531985 Free PMC article.
Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making.
Boersma C, Atthobari J, Gansevoort RT, de Jong-Van den Berg LT, de Jong PE, de Zeeuw D, Annemans LJ, Postma MJ. Boersma C, et al. Pharmacoeconomics. 2006;24(6):523-35. doi: 10.2165/00019053-200624060-00001. Pharmacoeconomics. 2006. PMID: 16761901 Review.
Integrated multiple-microarray analysis and mendelian randomization to identify novel targets involved in diabetic nephropathy.
Fan C, Gao Y, Sun Y. Fan C, et al. Front Endocrinol (Lausanne). 2023 Jul 10;14:1191768. doi: 10.3389/fendo.2023.1191768. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37492198 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information